

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; NON-COMPLIANCE WITH THE LISTING RULES; AND

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that Dr. Meng Songdong (“**Dr. Meng**”) tendered his resignation to the Company in respect of his positions as an independent non-executive Director, chairman of the remuneration and appraisal committee (the “**Remuneration and Appraisal Committee**”) and member of audit committee (the “**Audit Committee**”) of the Company with effect from 29 April 2026 due to the requirements of his principal employer.

Dr. Meng confirmed that, as at 28 April 2026, he has no disagreement with the Board and there is no matter related to his resignation that needs to be brought to the attention of the Company’s shareholders (“**Shareholders**”).

The Board would like to take this opportunity to express its sincere appreciation to Dr. Meng for his invaluable contributions to the Company during his tenure of service.

NON-COMPLIANCE WITH THE LISTING RULES

Following the resignation of Dr. Meng with effect from 29 April 2026, the Board comprises eight members with only two independent non-executive Directors, the Audit Committee of the Company comprises only two members, the nomination committee (the “**Nomination Committee**”) of the Company comprises two members with only one independent non-executive Director and the

Remuneration and Appraisal Committee of the Company comprises two members with only one independent non-executive Director. As a result, the Company fails to meet: (i) the requirement under Rule 3.10(1) of the Listing Rules, which stipulates that every board of directors of a listed issuer must include at least three independent non-executive directors; (ii) the requirement under Rule 3.21 of the Listing Rules, which stipulates that the Audit Committee must comprise a minimum of three members; and (iii) the requirement under Rule 3.27A of the Listing Rules, which stipulates that the Nomination Committee must be chaired by the chairman of the board or an independent non-executive director and comprising a majority of independent non-executive directors.

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

In order to fill the vacancies of the independent non-executive Director, the Audit Committee, the Nomination Committee and the Remuneration and Appraisal Committee and procure the Company to re-comply with Rules 3.10(1), 3.21 and 3.25 of the Listing Rules as soon as practicable, the Board further announces that after due consideration and the receipt of the recommendation of the Nomination Committee, the Board has resolved to propose to appoint Dr. Zhu Xiaodong (“**Dr. Zhu**”) as the independent non-executive Director of the second session (the “**Second Session**”) of the Board (“**Proposed Appointment**”), which will end on the expiry date of the Second Session, subject to the passing of the relevant resolution by the Shareholders at the annual general meeting of the Company (“**AGM**”).

The biographical details of Dr. Zhu are set out below:

Dr. Zhu Xiaodong (朱曉東), aged 54, a Chinese national with permanent residency overseas, holds a Doctorate degree in Molecular Virology from the Institute of Microbiology, Chinese Academy of Sciences, Dr. Zhu graduated from Hebei University in 1994, and obtained a master’s degree from School of Chinese Academy of Sciences in 2000. Dr. Zhu was selected for the Beijing “Haiju Project” for high-level talents and recognized as a Zhongguancun “High-end Leading Talent” in 2012. In 2016, he was honored as an “E-Town New Innovation Project · Yiqilin Talent” in the first session and appointed as a Beijing Overseas High-level Talent and Specially Recruited Expert. Dr. Zhu also serves as a specially recruited professor at Ningxia Medical University and the School of Pharmaceutical Sciences of Hebei University.

From May 2021 to May 2024, Dr. Zhu served as the General Manager of Xuanzhu Combio Technology Co., Ltd(軒竹康明生物科技有限公司), Head of Biomacromolecule R&D and Deputy General Manager at Xuanzhu Biopharmaceutical Co., Ltd. (軒竹生物股份有限公司). From July 1994 to August 1997, he served as an assistant engineer at the New Drug R&D Center of North China Pharmaceutical (華北製藥新藥研發中心). From October 2004 to May 2012, he was a postdoctoral fellow and assistant Specialist at the University of California, San Francisco (UCSF).

Dr. Zhu has also confirmed that (i) he meets the independence criteria set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors which might affect his independence at the time of his appointment and as at the date of this announcement.

Dr. Zhu will enter into an independent non-executive director appointment letter with the Company. It is proposed that the term of office of Dr. Zhu will start from the day upon which his appointment as an independent non-executive Director is approved at the general meeting and end on the expiry date of the Second Session, and can be re-appointed after the expiry of his initial term of office. It is proposed that Dr. Zhu will receive a remuneration of RMB150,000 per annum (tax inclusive), which is determined by the Remuneration and Appraisal Committee with reference to his experience, responsibilities in the Company and general market conditions.

Save as disclosed in this announcement, as at the date of this announcement, Dr. Zhu (i) did not hold any directorships in other Hong Kong or overseas listed companies in the last three years, or hold any other positions in the Company or any of its subsidiaries; (ii) did not have any relationship with any Director, supervisor, senior management or substantial shareholders of the Company; and (iii) did not have or were deemed to have any interest or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporation (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Save as disclosed in this announcement, as at the date of this announcement, the Board is not aware of any other matters in relation to the Proposed Appointment that need to be brought to the attention of the Shareholders or any information that need to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (w) of the Listing Rules.

The Board has further resolved that subject to the passing of the relevant resolution by the Shareholders at the general meeting, the compositions of the Audit Committee, the Nomination Committee and the Remuneration and Appraisal Committee be changed upon the conclusion of the general meeting as follows:

Audit Committee:	Mr. Manfred Shiu Shu Ming (<i>Chairman</i>), Mr. Tang Jin and Dr. Zhu Xiaodong
Nomination Committee:	Dr. Zhu Xiaodong (<i>Chairman</i>), Dr. Tang Li and Mr. Manfred Shiu Shu Ming
Remuneration and Appraisal Committee:	Dr. Ye Chengang (<i>Chairman</i>), Dr. Qiu Rongguo and Dr. Zhu Xiaodong

GENERAL

A circular containing, among other things, details of the proposed appointment of Dr. Zhu Xiaodong as the independent non-executive Director as mentioned above and the notice of the AGM will be despatched to the Shareholders in due course.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 28 April 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Manfred Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.